No Data
No Data
Leerink Partners Sticks to Its Hold Rating for Q32 Bio (QTTB)
Express News | Q32 Bio Inc - Signal-Aa Part B Topline Data Readout on-Track for 1H'26
Express News | Q32 Bio Doses First Patients in Both Part a Open-Label Extension and Part B of Signal-Aa Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
Express News | Q32 Bio Files for Mixed Shelf of up to $200 Mln - SEC Filing
Q32 Bio Is Maintained at Equal-Weight by Wells Fargo